drugset / Trial / NCT02800447
Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol
RandomizedParallel-groupOpen-labelTreatment
Summary
1. To observe and compare the overall response rate (ORR) of baseline BEACOPP and ABVD regimens for patients with advanced Hodgkin's lymphoma. 2. To evaluate the safety of Natulan® in Chinese patients with advanced Hodgkin's lymphoma
Timeline
- Start
- 2016-06
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bleomycin | Unknown | 10 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 650 mg/m2 | Intravenous |
| Comparator | Dacarbazine | Small molecule | 375 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Prednisone | Other / unclassified | 40 mg/m2 | Oral |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Subject | procarbazine | Small molecule | 100 mg/m2 | Oral |